双侧颞顶叶连续θ爆发刺激治疗持续性幻听:德国多中心随机假对照三期试验
本试验在德国7家大学精神病医院纳入138例伴持续性言语幻听的精神分裂症谱系障碍成人,随机接受15次活性或假双侧颞顶叶连续θ爆发刺激(cTBS)。意向性分析显示活性组PSYRATS-AH评分下降优于假刺激组,两组不良事件发生率相似,提示cTBS安全有效。
要点
- 两组不良事件发生率均为33%,头痛最常见,活性组发生1例严重不良事件。
- 疗效仅覆盖治疗结束时的短期评估,维持策略与长期疗效尚待研究。
核心结论
- 序贯双侧颞顶叶cTBS持续3周对精神分裂症谱系障碍成人的言语幻听安全有效,可确立为一种治疗选择。
研究设计与样本
- 多中心、随机、假对照、三盲三期临床试验,在德国7家大学精神病医院开展,采用计划的两阶段适应性设计(NCT02670291)。
- 纳入18-65岁、持续言语幻听每周至少1次且持续至少3个月、PANSS阳性量表P3条目≥3分的成人,共138例随机1:1分组。
主要发现
- 85例不良事件中活性组43例、假组42例;发生不良事件的患者分别为活性组22/66(33%)、假组21/64(33%)。
- 头痛为两组最常见不良事件(活性组13例、假组17例);活性组发生1例严重不良事件。
关键数值与推荐
- 活性cTBS方案:15次治疗,每次左、右侧颞顶叶各600个脉冲,持续3周。
- 主要结局为PSYRATS-AH评分从基线至3周治疗结束的变化,在意向性治疗人群中分析。
临床怎么用
- 对药物和心理治疗抵抗的持续性言语幻听成人,可考虑在3周内实施双侧颞顶叶cTBS。
- 治疗期间需监测头痛等不良事件,并关注活性组出现的严重不良事件。
局限性
- 随访仅至治疗结束后1、3、6个月,维持策略、治疗预测因素和长期疗效尚需进一步研究。
- 研究未纳入有亲历经验者参与;未收集种族和族裔数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Auditory verbal hallucinations are a major burden for patients with schizophrenia spectrum disorder and are often resistant to pharmacological and psychotherapeutic interventions. Repetitive transcranial magnetic stimulation (rTMS) of the temporo-parietal cortex has been proposed as a treatment for persistent auditory verbal hallucinations. We aimed to compare the efficacy and safety of bilateral continuous theta burst stimulation (cTBS), a brief and efficient form of rTMS, in adults with auditory verbal hallucinations versus sham cTBS. METHODS: This multicentre, randomised, sham-controlled, triple-blind phase 3 clinical trial was conducted at seven German psychiatric university hospitals and followed a planned two-stage adaptive design. Eligible patients were aged 18-65 years, had experienced persistent auditory verbal hallucinations at least once per week for a minimum of 3 months, and scored 3 points or higher on item P3 (hallucinatory behaviour) of the clinician-rated Positive Scale of the Positive and Negative Syndrome Scale (PANSS). 138 adults with treatment-persistent auditory verbal hallucinations and schizophrenia spectrum disorder were randomly assigned (1:1) to receive 15 sessions of active (n=70) or sham cTBS (n=68) administered sequentially as 600 pulses to the left and 600 pulses to the right temporo-parietal cortex over a 3-week period. The primary outcome was the change in the auditory hallucinations subscale of the Psychotic Symptom Rating Scales (PSYRATS-AH) from baseline to the end of treatment at 3 weeks, analysed in the intention-to-treat population, which included all randomly assigned patients who received at least one stimulation session. Safety was assessed in all patients who received at least one stimulation session. Follow-up assessments were performed at 1, 3, and 6 months after the end of treatment. People with lived experience were not involved in the study. This trial was registered at ClinicalTrials.gov, NCT02670291. FINDINGS: Between Oct 24, 2015, and May 1, 2023, 2583 patients were screened for eligibility, of whom 138 patients were randomly assigned to active cTBS (n=70; 32 [46%] females and 38 [54%] males) or sham treatment (n=68; 24 [35%] females and 44 [65%] males). Race and ethnicity data were not collected. The primary intention-to-treat analysis (66 patients in the active cTBS group; 64 patients in the sham cTBS group), combining stages 1 and 2, showed patients in the active cTBS group had a significantly greater decrease in the PSYRATS-AH score at end of treatment than did patients in the sham cTBS group (-6·36 [SD 7·97] vs -3·74 [SD 5·79]; adjusted difference -2·36 [95% CI -4·71 to -0·01]; p=0·042). Overall, 85 adverse events (43 in the active cTBS group; 42 in the sham cTBS group) were reported in 22 (33%) of 66 patients in the active cTBS group and 21 (33%) of 64 patients in the sham cTBS group. Headache was the most common adverse event in both groups (n=13 active cTBS group vs n=17 sham cTBS group). One serious adverse event occurred in the active group. INTERPRETATION: Sequential bilateral temporo-parietal cTBS over 3 weeks was safe and effective for reducing auditory verbal hallucinations in adults with schizophrenia spectrum disorder. This trial establishes cTBS as a treatment option for the care of these patients. Further research is needed to evaluate maintenance strategies, identify treatment predictors, and assess long-term efficacy. FUNDING: German Research Foundation.
引用
- Plewnia C, Brendel B, Schwippel T, et al. Theta burst stimulation of temporo-parietal cortex regions for the treatment of persistent auditory hallucinations: a multicentre, randomised, sham-controlled, triple-blind phase 3 trial in Germany. Lancet Psychiatry. 2025. PMID: 40774272. doi:10.1016/S2215-0366(25)00202-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。